CLINICS 2012;67(7):711-717 16. Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab. 2005;31(3 Pt 1):255-60, http://dx.doi.org/10.1016/S1262-3636(07)70192-1. 17. Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab. 2004;17:143-50. 18. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther. 2003;25(2):472-84, http://dx.doi.org/10.1016/S0149-2918(03)80090-5. 19. Luis BJ, Bugos C, Dirnberger G, Atherton T. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2003;25(1):194-209, http://dx.doi.org/10.1016/S0149-2918(03)90025-7. 20. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial- dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39(2):257-65, http://dx.doi.org/10.1016/S0735-1097(01)01746-6. 21. Latt JA, Turner K. Evaluations of Trinder’s glucose oxidase method for measuring glucose in serum and urine. Clin Chem. 1975;21(12):1754-60. 22. Trivelli LA, Ranney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. New Engl J Med. 1971 284:353-57. 23. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 1986;129:101-23, http://dx.doi.org/10.1016/0076- 6879(86)29064-3. 24. Warnick GR, Knopp RH, Fitzpatrick V, Brauson L. Estimating low- density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. 1990;36(1):15-9. 25. Bouloux P, Perret D, Besser GM. Methodological considerations in the determination of plasma cathecolamines by high-performance liquid chromatography with electrochemical detection. Ann Clin Biochem 1985;22(Pt 2):194-203. 26. Clauss A. Rapid physiological coagulation method for determination of fibrinogen. Acta Haematol. 1957;17(4):237-46, http://dx.doi.org/ 10.1159/000205234. 27. Born GVR. Quantitative investigation into the aggregation of blood platelets. J Physiol. 1962;162:67-8. 28. Singer JM, Andrade DF. Analysis of longitudinal data. In Handbook of Statistics. Volume 18: Bio-Environmental and Public Health Statistics. eds. P.K. Sen and C.R. Rao. Amsterdam: North Holland.2000;115-60. Metabolic and vascular effects of antidiabetic drugs Machado HA et al. 29. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. In Richard D. Irwing ed. Applied Linear Statistical Models, 4. Ed. Ilinois. 1996:1408p. 30. Meaney E, Vela A, Samaniego V, Meaney A, Asbu´ n J, Zempoalteca JC, et al. Metformin, arterial function, intima-media thickness and nitrox- idation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol. 2008;35(8):895-903, http://dx.doi.org/10.1111/j.1440-1681.2008. 04920.x. 31. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007;153(3):445.e1-6, http://dx.doi.org/10.1016/ j.ahj.2006.11.005. 32. Huang Z, Lei MX, Liu L, Tang QB. Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed type 2 diabetic patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006;31(3):367-72. 33. Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H. Long term cardiovascular effects of oral antidiabetic agents in non- diabetic patients with insulin resistance: double blind, prospective, randomized study. Heart. 2005;91(5):589-94, http://dx.doi.org/10.1136/ hrt.2003.027722. 34. Clark HE, Matthews DR. The effect of glimepiride on pancreatic beta – cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non. insulin. dependent diabetes mellitus. Horm Metab Res. 1996;28(9):445-60. 35. Inoguchi T, Umeda F, Kakimoto M, Sako Y, Ishii H, Noda K, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate dispro- portionately elevated plasma proinsulin levels in patients with 2 diabetes. Endocr J. 2000;47(6):763-70, http://dx.doi.org/10.1507/ endocrj.47.763. 36. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest. 2007; 117(5):1226-9, http://dx.doi.org/10.1172/JCI32133. 37. Bansal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab. 2008;295(4):E751-E761, http://dx.doi.org/10.1152/ajpendo.90295.2008. 38. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003;29(4 Pt):6S44-52, http:// dx.doi.org/10.1016/S1262-3636(03)72787-6. 39. Wing LR, Hawksworth GM, Bennett B, Booth NA. Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. J Lab Clin Med. 1991;117(2):109-14. 40. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. For the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis. Arch Intern Med. 2010;170(21): 1892-9. 717